Shares of Dermira Inc. (NASDAQ:DERM) were up 2.4% on Thursday . The company traded as high as $31.90 and last traded at $31.77, with a volume of 88,124 shares changing hands. The stock had previously closed at $31.04.

A number of analysts have recently weighed in on DERM shares. Needham & Company LLC reiterated a “buy” rating and set a $46.00 target price on shares of Dermira in a research report on Wednesday, June 22nd. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Wednesday, June 22nd. Wedbush upped their target price on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. Finally, Leerink Swann reiterated a “buy” rating and set a $46.00 target price (up from $39.00) on shares of Dermira in a research report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $41.00.

The firm’s 50-day moving average price is $31.98 and its 200-day moving average price is $27.50. The company’s market cap is $1.15 billion.

Dermira (NASDAQ:DERM) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. Equities research analysts forecast that Dermira Inc. will post ($3.39) EPS for the current fiscal year.

In other news, CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $31.63, for a total value of $347,930.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief financial officer now directly owns 14,375 shares in the company, valued at $433,406.25. The disclosure for this sale can be found here.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.